Cardiology

A trial led by clinicians from Northwestern Medicine suggests the presence of ischemic leg symptoms could serve as a useful indicator for patients to help determine whether they will see a meaningful benefit from their walking program.

A case-controlled study of patients in the PREVEND study indicates HDL anti-inflammatory capacity could help identify patients at a greater risk of cardiovascular disease.

FDA, CDC recommended halting use of the one-shot vaccine at all federal sites.

An analysis of the CLARIFY registry is providing clinicians with further insight into the impact of diabetes in patients with chronic coronary syndromes, particularly the increased risk of stroke, myocardial infarction, and cardiovascular death.

HDL anti-inflammatory capacity was inversely associated with incident cardiovascular disease after the team used a fully adjusted model.

Our latest case report from Dr. Brady Pregerson features a man in his 40s presenting with shortness of breath and worsening leg edema. Can you determine the correct diagnosis?

Our latest case report from Dr. Brady Pregerson features a 20 y/o female brought to the emergency department by EMS for altered mental status. Check out the EKG and see if you can determine the diagnosis.

The risk of hypertension increased in pediatric patients with more complex surgery.

An analysis of the CLARIFY registry suggests patients with chronic coronary syndromes were 3 times more likely than the general population to have diabetes and these patients were at a greater risk of multiple adverse outcomes compared to their counterparts without diabetes.

A new study finds ambulatory telemedicine visits were exceptionally greater among minority communities through the pandemic.

An analysis of data from Cedars-Sinai medical centers suggests the shift to telemedicine during the pandemic led to a reduction in a number of diagnostic tests and medications prescribed when compared to rates of both during the pre-pandemic era.

An analysis of more than 4 million singleton births indicates children born at an early gestational age were at an increased risk of heart failure at multiple points throughout life when compared to their counterparts not considered preterm births.

An analysis of more than 8000 patients with HIV and hypertension suggests these patients may not be receiving the most efficacious antihypertensive agents and this could be placing these patients at increased risk of cardiovascular disease events or death.

The once-daily tablet is indicated for adult patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia

An analysis of the DAPA-HF trial indicates the impact of dapagliflozin were consistent across both men and women receiving the SGLT2 inhibitor.

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Dr. Nisha Parikh provides additional insight into the AHA's latest scientific statement, which highlights the need for greater attention and emphasis on the impact of adverse pregnancy outcomes on cardiovascular risk in women.

A study from the ESC Acute CardioVascular Care 2021 Online Congress is providing clinicians with further insight into the effects of psychosocial stress on the cardiovascular health of men.

High blood pressure at a younger age could forecast cardiovascular problems in adulthood.

The PCSK9 inhibitor was linked to 27% mean reduction in LDL-C over 12 weeks.

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

Announced in a statement by the FDA on April 1, the PCKS9 inhibitor alirocumab is now indicated as an add-on therapy for the treatment of homozygous familial hypercholesterolemia.

New phase 2 data from a 24-week assessment suggest the first-in-class drug could benefit exercise and pulmonary-vascular outcomes.

Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

A study from Canada is calling for additional attention to paid to the screening, diagnosis, and treatment of primary aldosteronism in adult patients.